MET and cancer: Previous studies have shown that withdrawal of MET tyrosine kinase receptor inhibition leads to a post-treatment increase in cancer cell proliferation due to a transient hyper-phosphorylation phase, which culminates in the “MET burst” [82], i.e., the “flare effect”.